Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 May 22;353(9166):1762-3.
doi: 10.1016/S0140-6736(99)01927-3.

Tacrolimus in refractory polymyositis with interstitial lung disease

C V Oddis, F C Sciurba, K A Elmagd, T E Starzl

Tacrolimus in refractory polymyositis with interstitial lung disease

C V Oddis et al. Lancet. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Response of serum CK to administration of several immunosuppressives in an anti-Jo-1 antibody-positive patient
Note decrease in serum CK in response to tacrolimus (TAC) and flare of myositis (CK increase accompanied by muscle weakness) with temporary discontinuation of drug. IVIG=intravenous immune globulin, AZA=azathioprone, MTX=methotrexate, CS-corticosteroids.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific antibodies define useful homogeneous patient groups. Medicine. 1991;70:360–374. - PubMed
    1. Jaffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379–387. - PubMed
    1. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in PM and DM. Semin Arthritis Rheum. 1988;18:29–37. - PubMed
    1. Thomson AW, Carroll PB, McCauley J, et al. FK 506: A novel immunosuppressant for treatment of autoimmune disease. Springer Semin Immunopathol. 1992;14:323–344. - PMC - PubMed
    1. Yocum DE. Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheumatic Dis Clin N Am. 1996;22:133–153. - PubMed

Publication types